We are pleased to invite investors and analysts to participate in our virtual event on Monday, 6 June 2022, highlighting Roche data presented during the congress scientific program from June 3 – 7 2022 and our early-stage oncology portfolio.

16:00 – 17:30 CEST / 15:00 - 16:30 BST
09:00 – 10:30 am CDT / 7:00 – 8:30 am PDT

The webinar will start with a presentation, followed by a Q&A session (live access to the speakers). The slides will be available for download at 15:00 CEST on the day of the event. > click here

Agenda 

Oncology late-stage portfolio update
Elena Bernedo-Arzac, SVP, Oncology Therapeutic Area Head

Key Data at ASCO 2022
- Glofitamab pivotal Ph1b data in 3L+DLBCL
- Polivy Asian sub-population data from Ph3 POLARIX in 1L DLBCL
Ginna Laporte, MD - VP, Global Head Lymphoma/CLL Clinical Development

Oncology early R&D update
Johanna Bendell, M.D., Head of Roche Pharma Research and Early Development (pRED) Oncology
Andy Chan, M.D., Ph.D. Senior Vice President, Research Biology, Genentech Research & Early Development (gRED)

Q&A

Access to virtual event (pre-registration required)
Please pre-register for our webinar here*.

Should you be unable to register for the webinar due to your company IT policy, please send an e-mail to investor.relations@roche.com.

A replay of the webcast will be available via > ir.roche.com

*privacy notice

Best regards,